[12] Patent
[11] Patent No.:GC0007527  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/125718
Date of the Decision to Grant the Patent:05/Apr/2018

[21] Application No.:GC 2012-21104

[22] Filing Date:25/4/2012

[30] Priority:

[33] State [32] Priority date [31] Priority No.
EP
EP
26/4/2011
15/9/2011
11305490.2
11306154.3

[72] Inventor: CASTAN Remi

[73] Owner: Sanofi , 54 rue La Bo├ętie, 75008, Paris , France

[74] Agent: Suleiman I. Al-Ammar Law Office

  

 

  

[51]IPC:
Int. Cl.7: [A61K38/17;A61K31/4745;A61K31/505;A61K31/519;A61P35/00]

[56] Cited Documents:

-Sanofi-Regeneron: Afiibercept Versus Placebo in Combination With Irinotecan and 5-FU in theTreatment of Patients With Metastatic Coiorectai Cancer After Failure of an Oxaiipiatin Based Regimen,CiinicaiTriais.gov 17 February 2011
-WO 2009/024667 A2 (AVENTIS PHARMA SA [FR];BISSERY MARIE-CHRISTINE [FR];CHIRON-BLONDEL M) 26 February 2009
-WO 2006/059012 A1 (AVENTIS PHARMA SA [FR]) 08 June 2006
 
Examiner: PH. Sultana K. AlOudah

[54] COMPOSITION COMPRISING AFLIBERCEPT, FOLINIC ACID, 5-FLUOROURACIL 5-FU AND IRINOTECAN FOLFIRI
[57] Abstract: Pharmaceutical composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinocetan (FOLFIRI) useful in the treatment of Colorectal cancer (CRC).
No. of claims: 24


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.